case_images: PMC8315135_01
case_images: (A) alpha fetoprotein (AFP) levels of this patient during the treatment of tomotherapy combined with Neoantigen Reactive T Cells. (B) The lymphocyte levels of this patient during the treatment of tomotherapy combined with Neoantigen Reactive T Cells.
case_images: fimmu-12-685126-g001.jpg
case_images: PMC8315135_01_fimmu-12-685126-g001.jpg
case_images: f1
case_images: AFP were listed in  Figure 1A . At the same time, the lymph number gradually increased, and the changes in lymphocytes after per cycle of NRT treatment were shown in  Figure 1B . After four cycle of NRT, the overall efficacy evaluation was SD, and only regular examination was continued.
case_images: Plain and enhanced MRI of lesions in different parts of patient in different periods. a-f: right anterior lobe of the liver; g-l: porta hepatis; m-o: left outer lobe of the liver. Efficacy evaluation: PD, Disease progression; SD, Stable disease; PR, Partial response; CR, Complete response.
case_images: fimmu-12-685126-g002.jpg
case_images: PMC8315135_01_fimmu-12-685126-g002.jpg
case_images: f2
case_images: The patient's imaging changes were shown in  Figure 2 .
case_images: The patient received different treatments at different times. Firstly, tomotherapy combined with Neoantigen Reactive T Cells based immunotherapy(2017-02 to 2017-08, SD). Secondly, PD-1 antibody combined with apatinib(2018-05 to 2018-07, PR). Finally, PD-1 antibody single-drug maintenance treatment (2018-07 until 2020-06, PR in porta hepatis and CR in left outer lobe).
case_images: fimmu-12-685126-g003.jpg
case_images: PMC8315135_01_fimmu-12-685126-g003.jpg
case_images: f3
case_images: The target lesion changes at different time points during and after the treatment were listed in  Table 2 .In order to intuitively reflect the patient's prognosis and clinical curative effect, we listed the entire treatment process in  Figure 3 .